Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Documenti analoghi

• Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®
  di: Christian Laveille, et al.
  Pubblicazione: (2024)
• Exposure–Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents
  di: Xiaofeng Wang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder
  di: David P. Walling, et al.
  Pubblicazione: (2024)
• Plasma and Urine Pharmacokinetics of Long‐Acting Injectable Omeprazole Following Intramuscular Administrations to Healthy Thoroughbred Horses
  di: Caitlin Harding, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetic Model‐Based Dose Selection of Extended‐Release Injectable Olanzapine (TV‐44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia
  di: Itay Perlstein, et al.
  Pubblicazione: (2026)